Furthermore, patients with MPN, regardless of their diagnosis or JAK2 mutational status, are characterized by upregulation of JAK-STAT signaling molecules, and the CALR mutation activates the JAK2-STAT5 signaling pathway (Rampal et al. 2014). Here, SOAT1 is linked to myeloproliferative neoplasm.